Related Experiment Video
Updated: Nov 17, 2025
03:19
Author Spotlight: Advancing Varicocele Treatment with Neuromuscular Electrical Stimulation
Published on: August 30, 2024
1.0K
Percutaneous Treatment of Venous Erectile Dysfunction
Hanno Hoppe1,2, Nicholas Diehm2,3
1SwissIntervention Microtherapy Center, Bern, Switzerland.
Frontiers in Cardiovascular Medicine
|February 19, 2021
Summary
Erectile dysfunction, often linked to vascular issues in older men, involves difficulty achieving erections. New endovascular treatments, like embolization for veno-occlusive dysfunction, are gaining traction.
Area of Science:
- Urology
- Vascular Medicine
- Men's Health
Background:
- Erectile dysfunction (ED) is a common condition affecting quality of life.
- Vascular causes are prevalent, particularly in aging populations.
- Venogenic ED, a subset of vascular ED, is increasingly recognized.
Purpose of the Study:
- To review the etiologies and therapeutic options for erectile dysfunction.
- To highlight the growing importance of venogenic causes.
- To discuss the role of endovascular treatments in managing ED.
Main Methods:
- Literature review of current research on erectile dysfunction.
- Analysis of epidemiological data on ED prevalence and causes.
- Overview of established and emerging treatment modalities.
Main Results:
- Vascular etiologies are a primary driver of ED, especially in elderly men.
- Venogenic causes represent a significant and growing area of concern.
- Endovascular treatments, including transcatheter embolization, are increasingly utilized.
Conclusions:
- Erectile dysfunction has complex origins, with vascular factors being highly significant.
- Understanding and treating venogenic ED is crucial.
- Endovascular interventions offer promising therapeutic avenues for ED management.
More Related Videos
Related Concept Videos
01:26Varicose Veins II: Diagnostic Studies and Interprofessional Care
71
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
71
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
331
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
331
01:29Venous Thrombosis III: Interprofessional Care
109
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
109
01:27Peripheral Artery Disease III: Interprofessional Care
111
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
111
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
323
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
323
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
283
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
283